Studies Stem Cell Transplant for AL Amyloidosis Patients
Observes a patient's own stem cell transplant for AL amyloidosis, a plasma cell disorder.
Plain-language title generated from the registry record
Registry title: Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-75 with newly diagnosed AL amyloidosis who can have an autologous stem cell transplant.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- Newly diagnosed AL amyloidosis, with abnormal M protein or free light chain in blood and/or urine. ECOG score 0-2.
- Biomarker or test result
- Abnormal M protein or free light chain in serum and/or urine.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Multiple myeloma
- Allergy to any of the treatment drugs
- Severe cardiovascular disease
- Serious physical disease or mental illness
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04210791, who can take part
Where in China
- National Clinical Research Center of Kidney Diseases, Jinling HospitalNanjing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nanjing University School of Medicine
- Trial code
- NCT04210791
- Record updated
- 26 February 2024
- Original description
This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the long-term efficacy and prognosis risk factors of autologous stem cell transplantation for the treatment of AL amyloidosis.Read full original descriptionShow less
Autologous Stem Cell Transplantation for Patients With AL Amyloidosis
This study mainly evaluated the efficacy and safety of autologous stem cell transplantation for the treatment of AL amyloidosis, the role of induction and maintenance therapy in autologous stem cell transplantation, and the long-term efficacy and prognosis risk factors of autologous stem cell transplantation for the treatment of AL amyloidosis.
Inclusion: Male or female; aged 18-75 years; Patients with newly diagnosed AL; Appropriate for autologous hematopoietic stem cell transplantation; Abnormal M protein or free light chain detected in serum and/or urine; ECOG score 0-2 points; Subjects (or their legal representatives) must sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.
Exclusion: hypersensitivity to any treatment drugs; Subjects have severe cardiovascular disease; Subjects have a serious physical disease and mental illnesses; Other conditions that researchers consider are not suitable for transplantation; Pregnant and breastfeeding women; Subjects suffering from multiple myeloma.